227 related articles for article (PubMed ID: 12750235)
1. Association of markers of insulin and glucose control with subsequent colorectal cancer risk.
Saydah SH; Platz EA; Rifai N; Pollak MN; Brancati FL; Helzlsouer KJ
Cancer Epidemiol Biomarkers Prev; 2003 May; 12(5):412-8. PubMed ID: 12750235
[TBL] [Abstract][Full Text] [Related]
2. Decreased peripheral blood mitochondrial DNA content is related to HbA1c, fasting plasma glucose level and age of onset in type 2 diabetes mellitus.
Xu FX; Zhou X; Shen F; Pang R; Liu SM
Diabet Med; 2012 Jul; 29(7):e47-54. PubMed ID: 22211946
[TBL] [Abstract][Full Text] [Related]
3. A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus.
Herz M; Johns D; Reviriego J; Grossman LD; Godin C; Duran S; Hawkins F; Lochnan H; Escobar-Jiménez F; Hardin PA; Konkoy CS; Tan MH
Clin Ther; 2003 Apr; 25(4):1074-95. PubMed ID: 12809958
[TBL] [Abstract][Full Text] [Related]
4. Increased blood glucose and insulin, body size, and incident colorectal cancer.
Schoen RE; Tangen CM; Kuller LH; Burke GL; Cushman M; Tracy RP; Dobs A; Savage PJ
J Natl Cancer Inst; 1999 Jul; 91(13):1147-54. PubMed ID: 10393723
[TBL] [Abstract][Full Text] [Related]
5. A randomised, controlled trial of self-monitoring of blood glucose in patients with type 2 diabetes receiving conventional insulin treatment.
Nauck MA; Haastert B; Trautner C; Müller UA; Nauck MA; Heinemann L;
Diabetologia; 2014 May; 57(5):868-77. PubMed ID: 24445534
[TBL] [Abstract][Full Text] [Related]
6. Metabolic syndrome components and colorectal adenoma in the CLUE II cohort.
Tsilidis KK; Brancati FL; Pollak MN; Rifai N; Clipp SL; Hoffman-Bolton J; Helzlsouer KJ; Platz EA
Cancer Causes Control; 2010 Jan; 21(1):1-10. PubMed ID: 19774471
[TBL] [Abstract][Full Text] [Related]
7. Improvement of glycaemic control in type 2 diabetes: favourable changes in blood pressure, total cholesterol and triglycerides, but not in HDL cholesterol, fibrinogen, Von Willebrand factor and (pro)insulin.
Becker A; van der Does FE; van Hinsbergh VW; Heine RJ; Bouter LM; Stehouwer CD
Neth J Med; 2003 Apr; 61(4):129-36. PubMed ID: 12852722
[TBL] [Abstract][Full Text] [Related]
8. A prospective study of plasma C-peptide and colorectal cancer risk in men.
Ma J; Giovannucci E; Pollak M; Leavitt A; Tao Y; Gaziano JM; Stampfer MJ
J Natl Cancer Inst; 2004 Apr; 96(7):546-53. PubMed ID: 15069117
[TBL] [Abstract][Full Text] [Related]
9. Control of glycemia and other cardiovascular disease risk factors in older adults with type 2 diabetes mellitus: data from the Adult Diabetes Control and Management.
Sazlina SG; Mastura I; Ahmad Z; Cheong AT; Adam BM; Jamaiyah H; Lee PY; Syed-Alwi SA; Chew BH; Sriwahyu T
Geriatr Gerontol Int; 2014 Jan; 14(1):130-7. PubMed ID: 23581598
[TBL] [Abstract][Full Text] [Related]
10. Plasma C-peptide, insulin-like growth factor-I, insulin-like growth factor binding proteins and risk of colorectal cancer in a nested case-control study: the Japan public health center-based prospective study.
Otani T; Iwasaki M; Sasazuki S; Inoue M; Tsugane S;
Int J Cancer; 2007 May; 120(9):2007-12. PubMed ID: 17266031
[TBL] [Abstract][Full Text] [Related]
11. Comparing incident diabetes as defined by fasting plasma glucose or by HbA(1c). The AusDiab, Inter99 and DESIR studies.
Soulimane S; Simon D; Shaw JE; Zimmet PZ; Vol S; Vistisen D; Magliano DJ; Borch-Johnsen K; Balkau B
Diabet Med; 2011 Nov; 28(11):1311-8. PubMed ID: 21824186
[TBL] [Abstract][Full Text] [Related]
12. The effect of a thiazolidinedione drug, troglitazone, on glycemia in patients with type 2 diabetes mellitus poorly controlled with sulfonylurea and metformin. A multicenter, randomized, double-blind, placebo-controlled trial.
Yale JF; Valiquett TR; Ghazzi MN; Owens-Grillo JK; Whitcomb RW; Foyt HL
Ann Intern Med; 2001 May; 134(9 Pt 1):737-45. PubMed ID: 11329231
[TBL] [Abstract][Full Text] [Related]
13. Gender difference in the association of insulin and the insulin-like growth factor axis with colorectal neoplasia.
Yamaji T; Iwasaki M; Sasazuki S; Tsugane S
Int J Obes (Lond); 2012 Mar; 36(3):440-7. PubMed ID: 21673650
[TBL] [Abstract][Full Text] [Related]
14. Differential regulations of lipid profiles between Japanese responders and nonresponders treated with pioglitazone.
Kutoh E
Postgrad Med; 2011 Jan; 123(1):45-52. PubMed ID: 21293083
[TBL] [Abstract][Full Text] [Related]
15. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes.
Raskin P; Rendell M; Riddle MC; Dole JF; Freed MI; Rosenstock J;
Diabetes Care; 2001 Jul; 24(7):1226-32. PubMed ID: 11423507
[TBL] [Abstract][Full Text] [Related]
16. Biomarker patterns of inflammatory and metabolic pathways are associated with risk of colorectal cancer: results from the European Prospective Investigation into Cancer and Nutrition (EPIC).
Aleksandrova K; Jenab M; Bueno-de-Mesquita HB; Fedirko V; Kaaks R; Lukanova A; van Duijnhoven FJ; Jansen E; Rinaldi S; Romieu I; Ferrari P; Murphy N; Gunter MJ; Riboli E; Westhpal S; Overvad K; Tjønneland A; Halkjær J; Boutron-Ruault MC; Dossus L; Racine A; Trichopoulou A; Bamia C; Orfanos P; Agnoli C; Palli D; Panico S; Tumino R; Vineis P; Peeters PH; Duell EJ; Molina-Montes E; Quirós JR; Dorronsoro M; Chirlaque MD; Barricarte A; Ljuslinder I; Palmqvist R; Travis RC; Khaw KT; Wareham N; Pischon T; Boeing H
Eur J Epidemiol; 2014 Apr; 29(4):261-75. PubMed ID: 24791703
[TBL] [Abstract][Full Text] [Related]
17. Higher morning to evening ratio in total dose of twice-daily biphasic insulin analog might be effective in achieving glucose control in patients with poorly controlled type 2 diabetes.
Lee YH; Lee BW; Kwon HJ; Kang ES; Cha BS; Lee HC
Diabetes Technol Ther; 2012 Jun; 14(6):508-14. PubMed ID: 22376081
[TBL] [Abstract][Full Text] [Related]
18. Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women.
Kaaks R; Toniolo P; Akhmedkhanov A; Lukanova A; Biessy C; Dechaud H; Rinaldi S; Zeleniuch-Jacquotte A; Shore RE; Riboli E
J Natl Cancer Inst; 2000 Oct; 92(19):1592-600. PubMed ID: 11018095
[TBL] [Abstract][Full Text] [Related]
19. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group.
Yki-Järvinen H; Dressler A; Ziemen M;
Diabetes Care; 2000 Aug; 23(8):1130-6. PubMed ID: 10937510
[TBL] [Abstract][Full Text] [Related]
20. Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets - the TITRATE study.
Blonde L; Merilainen M; Karwe V; Raskin P;
Diabetes Obes Metab; 2009 Jun; 11(6):623-31. PubMed ID: 19515182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
